Works by Ruggles, James A.

Results: 14

Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 40, doi. 10.1111/dom.12763

By:

Frías, Juan P.;
Nakhle, Samer;
Ruggles, James A.;
Zhuplatov, Sergey;
Klein, Eric;
Zhou, Rong;
Strange, Poul

Publication type:

Article

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes.

Published in:

Diabetes Care, 2005, v. 28, n. 3, p. 632, doi. 10.2337/diacare.28.3.632

By:

Ceriello, Antonio;
Piconi, Ludovica;
Quagliaro, Lisa;
Yan Wang;
Schnabel, Catherine A.;
Ruggles, James A.;
Gloster, Maurice A.;
Maggs, David G.;
Weyer, Christian

Publication type:

Article

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Published in:

2003

By:

Weyer, Christian;
Gottlieb, Alan;
Kim, Dennis D.;
Lutz, Karen;
Schwartz, Sherwyn;
Gutierrez, Maria;
Wang, Yan;
Ruggles, James A.;
Kolterman, Orville G.;
Maggs, David G.

Publication type:

journal article

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes.

Published in:

Diabetes Care, 2002, v. 25, n. 4, p. 724, doi. 10.2337/diacare.25.4.724

By:

Whitehouse, Fred;
Kruger, Davida F.;
Fineman, Mark;
Shen, Larry;
Ruggles, James A.;
Maggs, David G.;
Weyer, Christian;
Kolterman, Orville G.

Publication type:

Article

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment.

Published in:

2016

By:

Blevins, Thomas;
Ruggles, James;
Hardy, Elise

Publication type:

Report

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

Published in:

American Journal of Health-System Pharmacy, 2005, v. 62, n. 2, p. 173., doi. 10.1093/ajhp/62.2.173

By:

Kolterman, Orville G.;
Kim, Dennis D.;
Shen, Larry;
Ruggles, James A.;
Nielsen, Loretta L.;
Fineman, Mark S.;
Baron, Alain D.

Publication type:

Article

Dimeric structure of the Oxytricha nova telomere end-binding protein α-subunit bound to ssDNA.

Published in:

Nature Structural Biology, 2002, v. 9, n. 3, p. 182

By:

Peersen, Olve B.;
Ruggles, James A.;
Schultz, Steve C.

Publication type:

Article

Effect of Pramlintide on Weight in Overweight and Obese Insulin-Treated Type 2 Diabetes Patients<sup>**</sup>.

Published in:

Obesity (19307381), 2004, v. 12, n. 4, p. 661, doi. 10.1038/oby.2004.76

By:

Hollander, Priscilla;
Maggs, David G.;
Ruggles, James A.;
Fineman, Mark;
Shen, Larry;
Kolterman, Orville G.;
Weyer, Christian

Publication type:

Article

A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.

Published in:

2016

By:

Hauber, A. Brett;
Nguyen, Hiep;
Posner, Joshua;
Kalsekar, Iftekhar;
Ruggles, James

Publication type:

journal article

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Published in:

Diabetes/Metabolism Research & Reviews, 2004, v. 20, n. 1, p. 55, doi. 10.1002/dmrr.419

By:

David G. Maggs;
Mark Fineman;
Jonathan Kornstein;
Terrie Burrell;
Sherwyn Schwartz;
Yan Wang;
James A. Ruggles;
Orville G. Kolterman;
Christian Weyer

Publication type:

Article

Direct Determination of Copper in Solids and Ores by Laser Ablation-Direct Current Argon Plasma Emission Spectrometry.

Published in:

Analytical Letters, 1985, v. 18, n. 14, p. 1723, doi. 10.1080/00032718508064474

By:

Mitchell, Peter G.;
Ruggles, James A.;
Sneddon, Joseph;
Radziemski, Leon J.

Publication type:

Article

6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-6-LB

By:

CLEGG, LINDSAY E.;
PENLAND, ROBERT C.;
BOULTON, DAVID W.;
BACHINA, SRINIVAS;
THURESSON, MARCUS;
HEERSPINK, HIDDO L.;
GUSTAVSON, STEPHANIE;
SJöSTRöM, C. DAVID;
RUGGLES, JAMES A.;
HERNANDEZ, ADRIAN F.;
BUSE, JOHN B.;
MENTZ, ROBERT J.;
HOLMAN, RURY R.

Publication type:

Article

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.

Published in:

2017

By:

Busch, Robert S.;
Ruggles, James;
Han, Jenny;
Hardy, Elise

Publication type:

journal article

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Published in:

Cardiovascular Diabetology, 2019, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12933-019-0942-x

By:

Clegg, Lindsay E.;
Penland, Robert C.;
Bachina, Srinivas;
Boulton, David W.;
Thuresson, Marcus;
Heerspink, Hiddo J. L.;
Gustavson, Stephanie;
Sjöström, C. David;
Ruggles, James A.;
Hernandez, Adrian F.;
Buse, John B.;
Mentz, Robert J.;
Holman, Rury R.

Publication type:

Article